Belite Bio
BLTE
156.08
+0.47
+0.30%
Belite Bio
US · BLTE
#1866 by market cap
Listed 2022
156.08
+0.47
+0.30%
Live - 5344 symbols - heartbeat 462s ago
· 2026-10-08 06:30
Pre-market
155.99
-0.06%
After-hours
156.08
0.00%
- Market cap
- 6.29B
- P/E (TTM)i
- -56.96
- P/Bi
- 8.09
- EPSi
- -2.31
- Div yieldi
- 0.00%
- 52W posi
- 64%
Reader sentiment
Are you bullish or bearish on BLTE?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 6 years
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 2.06M | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
| Research & development | 3.69M | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
| Operating profit | -5.74M | -9.80M | -12.82M | -31.67M | -40.00M | -84.21M |
| Pretax profit | -5.75M | -9.67M | -12.65M | -31.62M | -36.14M | -77.61M |
| Tax | 1.00K | 0 | 0 | 9.00K | 6.00K | 0 |
| Net profit | -5.75M | -9.67M | -12.65M | -31.63M | -36.14M | -77.61M |
| Basic EPS | 0 | 0 | -1 | -1 | -1 | -2 |
| Diluted EPS | -0.24 | -0.40 | -0.63 | -1.19 | -1.18 | -2.31 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.12M | 6.55M | 12.71M | 13.45M | 17.02M | 16.69M |
| Research & development | 9.40M | 11.05M | 10.31M | 14.62M | 15.66M | 18.21M |
| Operating profit | -15.52M | -17.60M | -23.02M | -28.08M | -32.68M | -34.91M |
| Pretax profit | -14.28M | -16.32M | -21.69M | -25.32M | -26.94M | -28.36M |
| Tax | -- | 0 | 0 | 0 | -- | 55.00K |
| Net profit | -14.28M | -16.32M | -21.69M | -25.32M | -26.94M | -28.41M |
| Basic EPS | 0 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.45 | -0.50 | -0.65 | -0.70 | -0.68 | -0.70 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 25.67M | 17.43M | 42.81M | 89.94M | 147.07M | 494.27M |
| Cash & ST investments | 25.62M | 17.34M | 42.09M | 88.16M | 145.15M | 492.42M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 25.74M | 18.35M | 44.27M | 94.64M | 152.13M | 780.56M |
| Total current liabilities | 972.00K | 1.64M | 2.10M | 3.63M | 6.05M | 9.88M |
| Short-term debt | -- | -- | 198.00K | 308.00K | 276.00K | 241.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 32,778,000.00 | 33,441,000.00 | 2,772,000.00 | 4,211,000.00 | 6,311,000.00 | 10,070,000.00 |
| Total equity | -7.04M | -15.09M | 41.50M | 90.43M | 145.82M | 770.49M |
| Retained earnings | -17.56M | -27.22M | -39.87M | -71.50M | -107.65M | -185.26M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 159.29M | 150.97M | 277.21M | 494.27M | 521.86M | 501.60M |
| Cash & ST investments | -- | -- | 275.61M | 492.42M | -- | -- |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 164.20M | 156.41M | 282.39M | 780.56M | 811.27M | 791.58M |
| Total current liabilities | -- | -- | 8.07M | 9.88M | -- | -- |
| Short-term debt | -- | -- | 265.00K | 241.00K | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 6,131,000.00 | 6,522,000.00 | 8,311,000.00 | 10,070,000.00 | 15,483,000.00 | 14,946,000.00 |
| Total equity | 158.07M | 149.89M | 274.08M | 770.49M | 795.79M | 776.64M |
| Retained earnings | -- | -- | -159.93M | -185.26M | -- | -- |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -4.44M | -7.47M | -11.46M | -29.84M | -29.23M | -36.99M |
| Depreciation & amortization | 17.00K | 30.00K | 198.00K | 399.00K | 449.00K | 464.00K |
| Free cash flow | -4.46M | -7.55M | -11.85M | -29.90M | -29.39M | -37.17M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 500.00K | 0 | 37.99M | 55.19M | 42.24M | 182.02M |
| Ending cash balance | 25.62M | 17.34M | 42.09M | 88.16M | 31.68M | 352.93M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -10.39M | -- | -- |
| Depreciation & amortization | -- | -- | -- | 117.00K | -- | -- |
| Free cash flow | -- | -- | -- | -10.56M | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 28.97M | -- | -- |
| Ending cash balance | -- | -- | -- | 352.93M | -- | -- |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -95.79 | -47.95 | -30.60 | -16.94 |
| ROA %i | -22.35 | -43.85 | -40.40 | -45.54 | -29.29 | -16.64 |
| ROIC %i | -- | -- | -89.94 | -47.38 | -32.89 | -18.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 26.41 | 10.66 | 20.35 | 24.76 | 24.31 | 50.02 |
| Quick ratioi | 26.40 | 10.62 | 20.01 | 24.50 | 24.09 | 49.90 |
| Debt / assetsi | -- | 0.00 | 1.96 | 0.94 | 0.35 | 0.06 |
| LT debt / equityi | -- | -- | 1.61 | 0.64 | 0.18 | 0.02 |
| Interest coveragei | -272.90 | -- | -789.50 | -1,263.92 | -1,805.90 | -38,804.50 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -33.43 | -37.34 | -32.30 | -16.94 | -18.93 | -22.10 |
| ROA %i | -32.07 | -35.93 | -31.33 | -16.64 | -18.51 | -21.60 |
| ROIC %i | -33.43 | -37.34 | -34.65 | -18.37 | -18.93 | -22.10 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 34.37 | 50.02 | -- | -- |
| Quick ratioi | -- | -- | 34.17 | 49.90 | -- | -- |
| Debt / assetsi | -- | -- | 0.18 | 0.06 | -- | -- |
| LT debt / equityi | -- | -- | 0.09 | 0.02 | -- | -- |
| Interest coveragei | -- | -- | -- | -38,804.50 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 06:30:46 · For reference only, not investment advice and not tailored to your situation.